Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02013700 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
A Phase 1 study, sponsored by Joshua M Hare.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02013700 is a Phase 1 study that was terminated before completion, run by Joshua M Hare. The registered enrollment target is 9 participants.
The verdict
NCT02013700, a Phase 1 study, was terminated before completion, sponsored by Joshua M Hare.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a phase I, randomized, blinded, placebo-controlled 9 subjects pilot safety run-in followed by an additional 16 randomized subjects for a total of 25 subjects. In the pilot phase subjects will be randomized into three treatment groups of allogenic mesenchymal stem cells and in the randomized phase subjects will receive either allogenic mesenchymal stem cells or matched placebo.
Interventions
- BIOLOGICAL Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)
- BIOLOGICAL matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-11-13 |
| Est. Completion | 2016-11-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02013700
The ClinicalTrials.gov registry entry for NCT02013700 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joshua M Hare, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs) is the first listed.
NCT02013700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02013700 about?
NCT02013700 is a clinical study titled "Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)". This is a phase I, randomized, blinded, placebo-controlled 9 subjects pilot safety run-in followed by an additional 16 randomized subjects for a total of 25 subjects. In the pilot phase subjects will be randomized into three treatment groups of allogenic mesenchymal stem cells and in the randomized ...
What is the current status of trial NCT02013700?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-11-13. Estimated completion is 2016-11-24.
What interventions are being tested in trial NCT02013700?
The interventions under investigation include: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs) (BIOLOGICAL), matched placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02013700?
This trial is sponsored by Joshua M Hare, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.